Tumour heterogeneity represents an ongoing challenge in the field of cancer therapy. Heterogeneity is evident between cancers from different patients and within a single tumour. The latter includes phenotypic diversity such as cell surface markers, (epi)genetic abnormality, growth rate, apoptosis and other hallmarks of cancer that eventually drive disease progression and treatment failure. Cancer stem cells (CSCs) have been put forward to be one of the non-genetic determining factors that contribute to intra-tumour heterogeneity.
In this ninth edition of Medicine at the Crick, we will review our current understanding of cancer stem cells, their role in initiation, progression and chemoresistance. We will also discuss new therapeutic avenues to eradicate these cells.
We plan to hold this as a hybrid event with a limited in person audience alongside online attendees.
Register on EventBrite and full joining details for all attendees will be sent in advance of the event.
Axel Behrens Scientific Director, CRUK Convergence Science Centre
Institute of Cancer Research and Imperial College London
John E. Dick PhD FRS Canada Research Chair in Stem Cell Biology
Senior Scientist, Princess Margaret Cancer Centre, University Health Network
Professor- Department of Molecular Genetics, University of Toronto
Simona Parrinello Professor of Neuro-oncology &Co-lead of the UCL Cancer Research UK Brain Tumour Centre of Excellence
Department of Cancer Biology, UCL Cancer Institute
Jeremy N. Rich, MD, MHS, MBA Deputy Director for Research, UPMC Hillman Cancer Center
Pittsburgh Foundation Chair in Personalized Cancer Therapies
Professor, Department of Neurology
Professor Dominique Bonnet The Francis Crick Institute
